This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Aegerion Target of SEC Probe Related to Drug Sales Practices

01/13/15 - 09:12 AM EST

Aegerion Target of SEC Probe Related to Drug Sales Practices Aegerion slipped disclosure of the SEC probe into an regulatory filing last night.

READ FULL POST

Bristol-Myers Checkpoint Inhibitor Prolongs Lung Cancer Patient Survival

01/12/15 - 07:07 AM EST

Bristol-Myers Checkpoint Inhibitor Prolongs Lung Cancer Patient Survival Lung cancer is a larger commercial market opportunity for Bristol's Opdivo and Merck's Keytruda.

READ FULL POST

'Free the Webcast!' Investor Transparency Gains Momentum at 'JPM15' Healthcare Confab

01/09/15 - 02:56 PM EST

'Free the Webcast!' Investor Transparency Gains Momentum at 'JPM15' Healthcare Confab Following a week of awareness raising through phone calls, Twitter and a Loncar guest appearance on CNBC, the number of JPM breakout session webcasts has increased significantly.

READ FULL POST

Brainstorm Stem-Cell Therapy Continues to Show Treatment Effect in ALS Patients

01/05/15 - 10:52 AM EST

Brainstorm Stem-Cell Therapy Continues to Show Treatment Effect in ALS Patients Final results from a mid-stage study of Brainstorm's NurOwn therapy show a slowing of disease progression in some ALS patients.

READ FULL POST

Abbvie's Hep C Regimen Approved, Marketing Battle With Gilead Up Next

12/19/14 - 04:16 PM EST

Abbvie's Hep C Regimen Approved, Marketing Battle With Gilead Up Next U.S. regulators approved a new hepatitis C therapy from Abbvie, heralding a new era of market competition with Gilead Sciences.

READ FULL POST

Orexigen's 'Goldilocks' Weight-Loss Pill is Just Right for European Regulators

12/19/14 - 08:25 AM EST

Orexigen's 'Goldilocks' Weight-Loss Pill is Just Right for European Regulators European regulators recommended the approval of Orexigen Therapeutics weight-loss pill on Friday, opening a new commercial market opportunity closed off to the company's competitors.

READ FULL POST

Where Are They Now? A Look Back at the Best & Worst Biotech CEOs

12/16/14 - 11:20 AM EST

Where Are They Now? A Look Back at the Best & Worst Biotech CEOs One biotech CEO won accolades in 2010 only to be razzed for poor performance in 2011.

READ FULL POST

Former Onyx CEO Returns to Biotech to Launch Boston Start Up

12/15/14 - 09:23 AM EST

Former Onyx CEO Returns to Biotech to Launch Boston Start Up Tony Coles, the former CEO of Onyx sold to Amgen for $10 billion in late 2013, is launching Yumanity Therapeutics focused on developing drugs for neuro-degenerative diseases.

READ FULL POST

Array Biopharma Regains Rights to Cancer Drug From Novartis

12/03/14 - 04:01 PM EST

Array Biopharma Regains Rights to Cancer Drug From Novartis The re-acquisition of binimetinib by Array was expected after Novartis announced in April a business swap with GlaxoSmithKline GSK which included the acquisition of Glaxo's cancer drug business.

READ FULL POST

Amgen Wins U.S. Approval for Immunotherapy Against Leukemia

12/03/14 - 01:31 PM EST

Amgen Wins U.S. Approval for Immunotherapy Against Leukemia Wednesday's approval of Blincyto comes more than five months ahead of the expected May 19, 2015 approval decision date.

READ FULL POST

Adam Feuerstein is a senior columnist at TheStreet in charge of covering biotechnology and pharmaceutical stocks.

Feuerstein has been a financial journalist for more than 20 years. He joined TheStreet in 2001, leaving in 2005 for a two-year stint as a biotech analyst for a New York-based investment management firm. Feuerstein rejoined TheStreet in 2007. Prior to his work at TheStreet, Feuerstein wrote about Internet startups and business software for Upside.com. Covering the dot-com boom and bust of the 1990s and early 2000s made Feuerstein very cynical, a trait he applies to great effect by highlighting the often-overlooked risks of biotech stock investing. In what can only be considered a high compliment, a particularly promotional sell-side analyst once warned his clients that Feuerstein "attacks viciously".

Expand Bio +

Feuerstein lives near Boston with his wife, two kids and a yellow lab-golden retriever named Max. When Feuerstein is not writing article and blog posts for TheStreet, he's tweeting. In fact, when Feuerstein is working, he's tweeting. All the time. He also runs, bikes, watches a lot of English soccer matches (Go Spurs!) and loves to cook.

Close Bio -

Markets

Chart of I:DJI
DOW 17,749.82 -1.57 -0.01%
S&P 500 2,105.75 -2.82 -0.13%
NASDAQ 5,114.4490 +2.7160 0.05%

Adam's Tweets

Top Rated Stocks Top Rated Funds Top Rated ETFs